Cutaneous side effects of clinically relevant cytokine therapies;Kutane nebenwirkungen klinisch relevanter zytokintherapien

Deutsche Medizinische Wochenschrift

Volumn 128, Issue 34-35, 2003, Pages 1782-1787

  Trefzer, Uwe ^a   Hofmann, M ^a   Sterry, W ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; COLONY STIMULATING FACTOR 1; CYTOKINE; ERYTHROPOIETIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 25; LYMPHOTOXIN; PLATELET DERIVED GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ALOPECIA; AUTOIMMUNE DISEASE; CAPILLARY LEAK SYNDROME; CYTOKINE THERAPY; DESQUAMATION; EDEMA; ERYTHEMA; ERYTHEMA NODOSUM; GASTROINTESTINAL TOXICITY; GRANULOMATOUS INFLAMMATION; HUMAN; HYPERTRICHOSIS; IMMUNOTHERAPY; LICHEN PLANUS; PEMPHIGOID; PEMPHIGUS VULGARIS; POLYARTERITIS NODOSA; PRURITUS; PSORIASIS; PUSTULOSIS; PYODERMA GANGRENOSUM; RASH; RAYNAUD PHENOMENON; REVIEW; SARCOIDOSIS; SKIN NECROSIS; SKIN ULCER; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS; VITILIGO; XEROSIS; XEROSTOMIA;

ALOPECIA; CYTOKINES; DERMATITIS, EXFOLIATIVE; DRUG ERUPTIONS; ERYTHROPOIETIN; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERONS; INTERLEUKIN-2; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS; VITILIGO;

EID: 0042235345     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-41708     Document Type: Review

References (50)

1. Ahren B, Engman K, Lindblom A. Tolerance to long-term treatment of malignant midgut carcinoid with a highly purified human leukocyte alpha-interferon. Anticancer Res 1992; 12: 881-884
2. Ariyoshi K, Shinohara K, Ruirong X. Growth of eyebrow after alpha interferon administration. Am J Hematol 1996; 53: 50-51
3. Asadullah K, Docke WD, Sabat RV, Volk HD, Sterry W. The treatment of psoriasis with IL-10: rationale and review of the first clinical trials. Expert Opin Investig Drugs 2000; 9: 95-102
4. Asadullah K, Sterry W, Trefzer U. Cytokine therapy in dermatology. Exp Dermatol 2002; 11: 97-106
5. Atkins MB, Vachino G, Tilg HJ et al. Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy. J Clin Oncol 1992; 10: 1802-1809
6. Azagury M, Pauwels C, Kornfeld S, Bataille N, Perie G. Severe cutaneous reactions following interferon injections. Eur J Cancer 1996; 32A: 1821
7. Baluna R, Vitetta ES. Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology 1997; 37: 117-132
8. Biesma B, Willemse PH, Mulder NH et al. Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. Blood 1992; 80: 1141-1148
9. Buzaid AC, Atkins M. Practical guidelines for the management of biochemotherapy-related toxicity in melanoma. Clin Cancer Res 2001; 7: 2611-2619
10. Cavallo MG, Pozzilli P, Thorpe R. Cytokines and autoimmunity. Clin Exp Immunol 1994; 96: 1-7
11. Chang LW, Liranzo M, Bergfeld WF. Cutaneous side effects associated with interferon-alpha therapy: a review. Cutis 1995; 56: 144
12. Creutzig A, Freund M. Severe Raynaud's syndrome associated with interferon therapy. A case history. Angiology 1996; 47: 185-187
13. Curfs JH, Meis JF, Hoogkamp-Korstanje JA. A primer on cytokines: sources, receptors, effects, and inducers. Clin Microbiol Rev 1997; 10: 742-80
14. Dempke W, Von Poblozki A, Grothey A, Schmoll HJ. Human hematopoietic growth factors: old lessons and new perspectives. Anticancer Res 2000; 20: 5155-5164
15. Dohmen K, Miyamoto Y, Irie K, Takeshita T, Ishibashi H. Manifestation of cutaneous polyarteritis nodosa during interferon therapy for chronic hepatitis C associated with primary biliary cirrhosis. J Gastroenterol 2000; 35: 789-793
16. Dummer R, Miller K, Eilles C, Burg G. The skin: an immunoreactive target organ during interleukin-2 administration? Dermatologica 1991; 183: 95-99
17. Fleming TE, Mirando WS, Soohoo LF et al. An inflammatory eruption associated with recombinant human IL-6. Br J Dermatol 1994; 130: 534-536
18. Fukutoku M, Shimizu S, Ogawa Y et al. Sweet's syndrome during therapy with granulocyte colony-stimulating factor in a patient with aplastic anaemia. Br J Haematol 1994; 86: 645-648
19. Groopman JE, Molina JM, Scadden DT. Hematopoietic growth factors. Biology and clinical applications. N Engl J Med 1989; 321: 1449-1459
20. Hauschild A, Hinrichsen H, Christophers E. Side-effects of interferon therapy in their management. Hautarzt 2000; 51: 793-800
21. Hoekman K, von Blomberg-van der Flier BM, Wagstaff J, Drexhage HA, Pinedo HM. Reversible thyroid dysfunction during treatment with GM-CSF. Lancet 1991; 338: 541-542
22. Jain KK. Cutaneous vasculitis associated with granulocyte colony-stimulating factor. J Am Acad Dermatol 1994; 31: 213-215
23. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001; 6: 34-55
24. Jones GJ, Itri LM. Safety and tolerance of recombinant interferon alfa-2a (Roferon-A) in cancer patients. Cancer 1986; 57: 1709-1715
25. Kelso A. Cytokines and their receptors: an overview. Ther Drug Monit 2000; 22: 40-43
26. Kinnunen E, Timonen T, Pirttila T et al. Effects of recombinant alpha-2b-interferon therapy in patients with progressive MS. Acta Neurol Scand 1993; 87: 457-460
27. Kutting B, Bohm M, Luger TA, Bonsmann G. Oropharyngeal lichen planus associated with interferon-alpha treatment for mycosis fungoides: a rare side-effect in the therapy of cutaneous lymphomas. Br J Dermatol 1997; 137: 836-837
28. Lee RE, Gaspari AA, Lotze MT, Chang AE, Rosenberg SA. Interleukin 2 and psoriasis. Arch Dermatol 1988; 124: 1811-1815
29. Mahler SJ, De Villez RL, Pulitzer DR. Transient acantholytic dermatosis induced by recombinant human interleukin 4. J Am Acad Dermatol 1993; 29: 206-209
30. Marinho RT, Johnson NW, Fatela NM et al. Oropharyngeal pemphigus in a patient with chronic hepatitis C during interferon alpha-2a therapy. Eur J Gastroenterol Hepatol 2001; 13: 869-872
31. Montoto S, Bosch F, Estrach T, Blade J, Nomdedeu B, Nontserrat E. Pyoderma gangrenosum triggered by alpha2b-interferon in a patient with chronic granulocytic leukemia. Leuk Lymphoma 1998; 30: 199-202
32. Neglia V, Sookoian S, Herrera M et al. Development of cutaneous sarcoidosis in a patient with chronic hepatitis C treated with interferon alpha 2b. J Cutan Med Surg 2001; 5: 406-408
33. Nouri K, Busso M, Machler BC. Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C. Cutis 1997; 60: 289-290
34. Ohmoto K, Yamamoto S. Angioedema after interferon therapy for chronic hepatitis C. Am J Gastroenterol 2001; 96: 1311-1312
35. Orlow SJ, Friedman-Kien AE. Cutaneous ulcerations secondary to interferon alfa therapy of Kaposi's sarcoma. Arch Dermatol 1992; 128: 566
36. Parodi A, Semino M, Gallo R, Rebora A. Bullous eruption with circulating pemphigus-like antibodies following interferon-alpha therapy. Dermatology 1993; 186: 155-157
37. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271: 907-913
38. Ruddle NH. Tumor necrosis factor (TNF-alpha) and lymphotoxin (TNF-beta). Curr Opin Immunol 1992; 4: 327-332
39. Sanders S, Busam K, Tahan SR, Johnson RA, Sachs DJ. Granulomatous and suppurative dermatitis at interferon alfa injection sites: report of 2 cases. Am Acad Dermatol 2002; 46: 611-616
40. Schliesser G, Pralle H, Lohmeyer J. Leukocytoclastic vasculitis complicating granulocyte colony-stimulating factor (G-CSF) induced neutrophil recovery in T gamma-lymphocytosis with severe neutropenia. Ann Hematol 1992; 65: 151-152
41. Schroder-Kolb B. Cutaneous reactions to treatment with recombinant human erythropoietin. Derm Beruf Umwelt 1990; 38: 12-13
42. Semenzato G, Pizzolo G, Zambello R. The interleukin-2/interleukin-2 receptor system: structural, immunological, and clinical features. Int J Clin Lab Res 1992; 22: 133-142
43. Staunton MR, Scully MC, Le Boit PE, Aronson FR. Life-threatening bullous skin eruptions during interleukin-2 therapy. J Natl Cancer Inst 1991; 83: 56-57
44. Sundal E, Kaeser U. Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients. Nephrol Dial Transplant 1989; 4: 979-987
45. Tolaymat A, Leventhal B, Sakarcan A, Kashima H, Monteiro C. Systemic lupus erythematosus in a child receiving long-term interferon therapy. J Pediatr 1992; 120: 429-432
46. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Safety 1994; 10: 115-150
47. Virgili A, Corazza M, Lombardi AR, Sighinolfi L. Cutaneous ulcers due to interferon seem not to be related to the dosage. J Eur Acad Dermatol Venereol 1999; 13: 141-143
48. Wolfer LU, Goerdt S, Schroder K, Zouboulis CC, Orfanos CE. Interferon-alpha-induced psoriasis vulgaris. Hautarzt 1996; 47: 124-128
49. Wolkenstein P, Chosidow O, Wechsler J et al. Cutaneous side effects associated with interleukin 2 administration for metastatic melanoma. J Am Acad Dermatol 1993; 28: 66-70
50. Yang SC, Grimm EA, Parkinson DR et al. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase 1 trial. Cancer Res 1991; 51: 3669-3676